Shopping Cart
- Remove All
Your shopping cart is currently empty
Argentina
Australia
Austria
Belgium
Brazil
Bulgaria
Croatia
Cyprus
Czech
Denmark
Egypt
Estonia
Finland
France
Germany
Greece
Hong Kong
Hungary
Iceland
India
Ireland
Israel
Italy
Japan
Korea
Latvia
Lebanon
Malaysia
Malta
Morocco
Netherlands
New Zealand
Norway
Poland
Portugal
Romania
Singapore
Slovakia
Slovenia
Spain
Sweden
Switzerland
Taiwan,China
Thailand
Turkey
United Kingdom
United States
Other Countries
Select your Country or Region
KB-5246
Contact us for more batch information
KB-5246
Catalog No. T11744Cas No. 119474-55-4
KB-5246, displays antibacterial activities.is a tetracyclic quinolone.
All TargetMol products are for research purposes only and cannot be used for human consumption. We do not provide products or services to individuals. Please comply with the intended use and do not use TargetMol products for any other purpose. | Pack Size | Price | Availability | Quantity |
|---|---|---|---|
| 25 mg | $1,670 | 6-8 weeks | |
| 50 mg | $2,180 | 6-8 weeks | |
| 100 mg | $2,800 | 6-8 weeks |
Bulk & Custom
Add to Cart
Questions
View MoreInhibitors Related to "KB-5246"
KRAS G12C inhibitor 58
T790572915599-52-7
KRAS G12C inhibitor 58 is utilized in cancer research as an inhibitor of the KRAS G12C mutation [1].
- Inquiry Price
Size
QTY
Kobe0065
Cited
T1876436133-68-5
Kobe0065 is a novel and effective small-molecule compound inhibiting Ras–Raf interaction by SBDD; shows potent activity to competitively inhibit the binding of H-Ras·GTP to c-Raf-1 RBD with a Ki value of 46 ± 13 μM.
- $39
Size
QTY
CitedKRAS G12D inhibitor 14
T622282765254-39-3
KRAS G12D inhibitor 14 is a potent inhibitor of KRAS G12D that binds KRAS G12D protein (Kd: 33 nM). KRAS G12D inhibitor 14 inhibits the active form of KRAS G12D (KRAS G12D-GTP), but not KRAS G13D.
- $247
Size
QTY
ARS-1630
T103761698055-86-5
ARS-1630 is a mutant K-ras G12C inhibitor. It is a less active enantiomer of ARS-1620.
- $84
Size
QTY
(S)-AMG-510
T222582252403-56-6
(S)-AMG-510 is an S-type compound of AMG-510, a potent covalent inhibitor of KRAS G12C with potential antitumor activity.
- $31
Size
QTY
Oncrasin-1
T800675629-57-1
Oncrasin 1 is a potent inhibitor of anticancer that kills various human lung cancer cells with K-Ras mutations at low or submicromolar concentrations
- $31
Size
QTY
Garsorasib
T401862559761-14-5
Garsorasib is an effective KRAS G12C inhibitor (IC50 = 10 nM) and can be used in studies about cancer treatment.
- $91
Size
QTY
MLS-573151
T2210610179-57-4
MLS-573151 is a selective inhibitor of GTPase Cdc42(EC50 of 2 μM). It is inactive against other GTPases family members, such as Rab2, Rab7, H-Ras, Rac1, Rac 2 and RhoA wild-type. MLS-573151 acts by blocking the binding of GTP to Cdc42.
- $34
Size
QTY
FTI-277 hydrochloride Cited
T2700180977-34-8
FTI-277 hydrochloride (FTI 277 HCl) is an effective and specific farnesyltransferase (FTase) inhibitor (IC50: 500 pM); this selectivity is about 100-fold than the closely related GGTase I.
- $48
Size
QTY
CitedKRAS inhibitor-9
T8756300809-71-6
KRAS inhibitor-9 (DUN09716) is a potent KRAS inhibitor with Kd of 92 μM that blocks the formation of GTP-KRAS and downstream activation of KRAS. KRAS inhibitor-9 causes G2/M cell cycle arrest and induces apoptosis. KRAS inhibitor-9 selectively inhibits the proliferation of NSC-LC cells with KRAS mutation but not normal lung cells
- $55
Size
QTY
Product Introduction
Bioactivity
Chemical Properties
Storage & Solubility Information
| Description | KB-5246, displays antibacterial activities.is a tetracyclic quinolone. |
| In vitro | KB5246, a tetracyclic quinolone with antibacterial properties, effectively inhibits 90% of Escherichia coli, Klebsiella pneumoniae, and Klebsiella oxytoca isolates at concentrations of 0.10 μg/mL or lower. Notably, concentrations of KB-5246 at or above the minimum inhibitory concentration (MIC) prevent regrowth of these organisms after 24 hours of incubation. Additionally, the MICs for 90% of tested isolates (MIC90s) against key gram-positive microorganisms, including methicillin-resistant Staphylococcus aureus, Staphylococcus epidermidis, Streptococcus pneumoniae, and Streptococcus pyogenes, are 0.39 μg/mL, showcasing KB-5246's broad-spectrum antibacterial efficacy. |
| In vivo | The 50% effective dose (ED50) of KB-5246 for treating S. pneumoniae 2132 infections is 50.5 mg/kg. Its efficacy against S. aureus Smith, P. aeruginosa GN11189, and Serratia marcescens GN7577 is on par with ofloxacin and surpasses that of norfloxacin. |
| Molecular Weight | 425.86 |
| Formula | C18H17ClFN3O4S |
| Cas No. | 119474-55-4 |
| Storage | Powder: -20°C for 3 years | In solvent: -80°C for 1 year |
Calculator
In Vivo Formulation Calculator (Clear solution)
Please enter your animal experiment information in the following box and click Calculate to obtain the mother liquor preparation method and in vivo formula preparation method:
For example, your dosage is 10 mg/kg Each animal weighs 20 g, and the dosage volume is 100 μL . A total of 10 animals were administered, and the formula you used is 5% 
DMSO+30% PEG300+5% Tween 80+60% ddH2O. So your working solution concentration is 2 mg/mL。 Mother liquor preparation method: 2 mg of drug dissolved in 50 μL DMSO (mother liquor concentration of 40 mg/mL), if you need to configure a concentration that exceeds the solubility of the product, please contact us first.
(mother liquor concentration of 40 mg/mL), if you need to configure a concentration that exceeds the solubility of the product, please contact us first.Dose Conversion
You can also refer to dose conversion for different animals. More
Tech Support
Please see Inhibitor Handling Instructions for more frequently ask questions. Topics include: how to prepare stock solutions, how to store products, and cautions on cell-based assays & animal experiments, etc
Preview
- TOP
Feedback
Hello! How can I help you today? 
Copyright © 2015-2024 TargetMol Chemicals Inc. All Rights Reserved.